NeoGenomics, Inc.
NASDAQ:NEOMedical - Diagnostics & Research
+$0.63 today
- Market cap
- $1.99B
- Beta
- 1.81
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.84
Volume 1.09M
Average 1.94M
NEO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
NeoGenomics, Inc.NASDAQ: NEO
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 5.9% from a year ago
Cash & equivalents stood at $145.54M at the end of Q2 FY2026, down 5.9% from a year earlier and down 0.4% from the prior quarter. Over 3 fiscal years it compounded at -15.4% a year.
Context
- Cash & equivalents amounted to 10.8% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -5.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 159.62M USD
- Year-over-year change
- -56.5%
- 4-year CAGR
- -15.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 159.62M | -56.5% |
| FY2024 | 2024-12-31 | 367.01M | +7.2% |
| FY2023 | 2023-12-31 | 342.49M | +30.1% |
| FY2022 | 2022-12-31 | 263.18M | -16.9% |
| FY2021 | 2021-12-31 | 316.83M | — |
Cash & Equivalents vs competitors
How NEO compares with its peers on the latest reported figures
- NEO's Jun 2026 cash & equivalents of $145.54M is the 3rd highest of the 10 companies compared; the peer median is $63.76M.
- Its year-over-year change of -5.9% is the 7th highest of 10, against a peer median of +35.5%.
- Cash & equivalents amounts to 10.8% of total assets for NEO, versus a peer median of 20.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.03B | +77.0% | +38.7% | 54.5% | |
| Jun 2026 | $299.52M | +36.5% | +33.0% | 20.2% | |
| Jun 2026 | $145.54M | -5.9% | -15.4% | 10.8% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
| Mar 2026 | $73.59M | +3.7% | +11.7% | 22.6% | |
| Mar 2026 | $63.76M | -28.9% | -1.7% | 11.6% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $60.32M | -18.6% | -8.6% | 12.5% |
| Jun 2026 | $55.65M | -56.3% | +1.1% | 2.0% | |
| Mar 2026 | $25.57M | +45.3% | -23.9% | 27.0% | |
| Mar 2026 | $21.51M | +92.2% | -19.8% | 41.4% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding NEO) | $63.76M | +35.5% | +1.1% | 20.2% | |
Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 316.83M | 263.18M | 342.49M | 367.01M | 159.62M |
| Short-term Investments | 198.56M | 174.81M | 72.72M | 19.83M | 0 |
| Net Receivables | 112.13M | 119.71M | 131.26M | 150.54M | 159.24M |
| Inventory | 23.4M | 24.28M | 24.16M | 26.75M | 28.57M |
| Other Current Assets | 18.24M | 8.08M | 8.2M | 11.72M | 7.42M |
| Total Current Assets | 681.51M | 605.29M | 596.81M | 596.02M | 376.29M |
| Property, Plant & Equipment (Net) | 211.66M | 198.61M | 183.78M | 173.69M | 163.28M |
| Goodwill | 527.12M | 522.77M | 522.77M | 522.77M | 524.34M |
| Intangible Assets | 442.33M | 408.26M | 373.13M | 339.68M | 286.53M |
| Long-term Investments | 236K | 31K | 0 | 0 | 0 |
| Tax Assets | 55.48M | 34.75M | 0 | 0 | 0 |
| Other Non-current Assets | (48.54M) | (29.67M) | 4.74M | 5.89M | 9.39M |
| Total Non-current Assets | 1.19B | 1.13B | 1.08B | 1.04B | 983.54M |
| Total Assets | 1.87B | 1.74B | 1.68B | 1.64B | 1.36B |
| Account Payables | 17.92M | 20.51M | 20.33M | 21.61M | 23.09M |
| Short-term Debt | 1.14M | 0 | 0 | 200.78M | 4.78M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.19M | 7.56M | 2.13M | 409K | 0 |
| Other Current Liabilities | 16.66M | 15.07M | 53.16M | 62.44M | 60.43M |
| Total Current Liabilities | 87.23M | 89.93M | 96.3M | 301.24M | 88.3M |
| Long-term Debt | 532.48M | 535.32M | 538.2M | 340.34M | 404.68M |
| Deferred Tax Liabilities | 55.48M | 34.75M | 24.29M | 21.51M | 18.22M |
| Deferred Revenue (Non-current) | 917K | 19K | 0 | 0 | 386K |
| Other Non-current Liabilities | 13.03M | 13.06M | 13.03M | 11.77M | (51.14M) |
| Total Non-current Liabilities | 674.27M | 652.08M | 643.39M | 434.46M | 434.97M |
| Total Liabilities | 761.5M | 742.01M | 739.69M | 735.7M | 523.27M |
| Common Stock | 124K | 127K | 127K | 128K | 129K |
| Retained Earnings | (14.84M) | (159.09M) | (247.06M) | (325.78M) | (433.81M) |
| Accumulated OCI | (638K) | (3.9M) | (1.67M) | (206K) | 4K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.11B | 998.02M | 941.54M | 902.34M | 836.56M |
| Total Debt | 612.79M | 610.93M | 611.68M | 605.33M | 472.28M |
| Net Debt | 295.96M | 347.75M | 269.19M | 238.32M | 312.66M |
NeoGenomics, Inc.
NASDAQ:NEO
Intrinsic Alpha fair value
Locked
Current Price
$15.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.